

# Hao-Wei Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4985382/publications.pdf>

Version: 2024-02-01

30  
papers

1,089  
citations

840776

11  
h-index

580821

25  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1506  
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndrome. BJR   case Reports, 2022, 8, .	0.2	0
2	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
3	CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood, 2022, 140, 451-463.	1.4	56
4	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkinâ€™s lymphoma. , 2021, 9, e002097.		28
5	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. Blood Advances, 2021, 5, 1660-1670.	5.2	35
6	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. Oncologist, 2021, 26, 288-e541.	3.7	10
7	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. Journal of Clinical Oncology, 2021, 39, 7036-7036.	1.6	0
8	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. JAMA Oncology, 2021, 7, 1678.	7.1	12
9	Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 2021, 138, 2469-2484.	1.4	79
10	Antigen Loss after Targeted Immunotherapy in Hematological Malignancies. Clinics in Laboratory Medicine, 2021, 41, 341-357.	1.4	7
11	Beyond the storm â€” subacute toxicities and late effects in children receiving CAR T cells. Nature Reviews Clinical Oncology, 2021, 18, 363-378.	27.6	37
12	Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. Aids, 2021, 35, 53-62.	2.2	6
13	Multicentric Castleman disease and the evolution of the concept. Pathologica, 2021, 113, 339-353.	3.4	11
14	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood, 2021, 138, 3837-3837.	1.4	8
15	Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. , 2020, 8, e001563.		22
16	Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. Leukemia and Lymphoma, 2020, 61, 3177-3187.	1.3	9
17	Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood, 2020, 136, 2229-2232.	1.4	26
18	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2020, 38, 1527-1538.	1.6	58

#	ARTICLE	IF	CITATIONS
19	Expression of the muscle-associated gene MYF6 in hairy cell leukemia. PLoS ONE, 2020, 15, e0227586.	2.5	5
20	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Journal of Clinical Oncology, 2020, 38, 1938-1950.	1.6	273
21	Molecular assessment of clonality in lymphoid neoplasms. Seminars in Hematology, 2019, 56, 37-45.	3.4	13
22	Flow Cytometric Immunophenotypic Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms. Cytometry Part B - Clinical Cytometry, 2019, 96, 338-350.	1.5	15
23	CD30 <sup>+</sup> large B cell lymphoma with anaplastic features and complete loss of B cell marker expression arising from follicular lymphoma. Histopathology, 2019, 75, 602-605.	2.9	3
24	Diagnosis of Hodgkin lymphoma in the modern era. British Journal of Haematology, 2019, 184, 45-59.	2.5	114
25	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. Blood, 2019, 134, 1536-1536.	1.4	1
26	Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica, 2018, 103, e215-e218.	3.5	131
27	A 47-year old female with a destructive sellar mass. Brain Pathology, 2017, 27, 241-242.	4.1	1
28	Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection. Leukemia Research Reports, 2017, 8, 4-6.	0.4	9
29	Multicentric Castleman disease: Where are we now?. Seminars in Diagnostic Pathology, 2016, 33, 294-306.	1.5	95
30	Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Molecular Genetics and Metabolism, 2016, 118, 55-59.	1.1	4